Overview

A Study to Evaluate Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment

Status:
Not yet recruiting

Trial end date:
2027-03-24

Target enrollment:

Participant gender:

Summary

This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with pembrolizumab, with or without chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Immunoglobulins
Irinotecan
Lenvatinib
Paclitaxel
Pembrolizumab